Replies to post #191728 on Biotech Values

[north40000]

I wonder what GILD et al would have done with that reimbursement model had it been offered in HCV therapy in the 1st place?

[DewDiligence]

In an “indication-specific pricing” model, the per-pill cost of Tarceva would be lower for pancreatic-cancer patients than for lung-cancer patients, given the reduced efficacy, [ESRX’s] Dr. Miller said.

Where different cancer indications use the same dosage, such an indication-based pricing scheme may be impractical insofar as it increases the incentives for fraudulent insurance claims.

[DewDiligence]

Italy becomes focus of pay-for-performance drug pricing:

http://www.bloomberg.com/news/articles/2016-01-15/when-new-cancer-treatments-fail-italy-wants-its-money-back